APPILI THERAPEUTICS INC - APLIF STOCK NEWS

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) announced that Dr. Don Cilla, President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, in Toronto. The presentation will highlight updates on Appili's pipeline, including ATI-1701, a tularemia vaccine funded by the U.S. Government, and ATI-1801, a treatment for cutaneous leishmaniasis. Both programs may qualify for FDA Priority Review Vouchers upon approval. The conference will include one-on-one meetings for investors. Appili Therapeutics focuses on developing novel anti-infectives to combat life-threatening infections.

Appili Therapeutics has appointed Dr. Gary Nabors as Chief Development Officer effective April 3, 2023. With over 25 years of experience in vaccine and antibody development, Dr. Nabors is expected to advance the company's programs, particularly ATI-1701 for tularemia and ATI-1801 for cutaneous leishmaniasis. Both candidates could qualify for FDA Priority Review Voucher upon approval. The announcement comes as Dr. Nabors represents Appili at the World Vaccine Congress in Washington, D.C., from April 3rd to 6th, 2023, to engage with industry leaders and trends in vaccine development.

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) has announced an amended loan agreement with Long Zone Holdings Inc. to receive an additional C$2.5 million as part of a secured loan to support working capital. This second tranche supplements the first tranche of US$3.6 million from the original loan agreement dated March 25, 2022. The total loan is due by March 15, 2025, with an interest rate of 11% per annum. The company expects to net C$2.2 million after fees. The agreement has been conditionally approved by the Toronto Stock Exchange.

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) reported its Q3 fiscal 2023 results, highlighting significant developments in its infectious disease and biodefense portfolio. The U.S. Department of Defense has approved approximately US$14 million funding for ATI-1701, a tularemia vaccine. The NDA for ATI-1501 has been accepted by the FDA, with a PDUFA date of September 23, 2023. Financially, the company reported a reduced net loss of $6.6 million for the nine months ending December 31, 2022, down from $21.8 million in the previous year, attributed to decreased research and development expenses. However, cash reserves fell to $1.4 million from $6.7 million.